The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: Comparison with 18F-FDG PET-CT

European Radiology

Volumn 19, Issue 6, 2009, Pages 1425-1434

  Beheshti, Mohsen ^a   Pöcher, Sigrid ^a   Vali, Reza ^a   Waldenberger, Peter ^a   Broinger, Gabriele ^a   Nader, Michael ^a   Kohlfürst, Susanne ^b   Pirich, Christian ^c   Dralle, Henning ^d   Langsteger, Werner ^a  

^a St Vincent's Hospital   (Austria)

^b GENERAL HOSPITAL KLAGENFURT   (Austria)

^c UNIVERSITY OF SALZBURG   (Austria)

^d MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

Author keywords

18F DOPA; 18F FDG; Medullary thyroid carcinoma; PET CT

Indexed keywords

CALCITONIN; CARCINOEMBRYONIC ANTIGEN; DOPA; FLUORODEOXYGLUCOSE F 18; IASODOPA; PENTAGASTRIN; UNCLASSIFIED DRUG; 6 FLUORODOPA F 18; DIAGNOSTIC AGENT; DRUG DERIVATIVE; RADIOPHARMACEUTICAL AGENT;

ADULT; ARTICLE; CALCITONIN BLOOD LEVEL; CLINICAL ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; HISTOPATHOLOGY; HUMAN; INTERMETHOD COMPARISON; MALE; MALIGNANT NEOPLASTIC DISEASE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; THYROID MEDULLARY CARCINOMA; TUMOR LOCALIZATION; COMPARATIVE STUDY; COMPUTER ASSISTED TOMOGRAPHY; EVALUATION; IMAGE SUBTRACTION; METHODOLOGY; MIDDLE AGED; POSITRON EMISSION TOMOGRAPHY; REPRODUCIBILITY; THYROID TUMOR;

DIHYDROXYPHENYLALANINE; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SUBTRACTION TECHNIQUE; THYROID NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 67349208753     PISSN: 09387994     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00330-008-1280-7     Document Type: Article

References (49)

1. Lairmore TC, Wells SA Jr (1991) Medullary carcinoma of the thyroid: current diagnosis and management. Sem Surg Oncol 7:92-99
2. Saad MF, Ordonez NG, Rashid RK et al (1984) Medullary carcinoma of the thyroid. A study of the clinical features and prognostic factors in 161 patients. Medicine 63:319-342
3. Brierley J, Tsang R, Simpson WJ et al (1996) Medullary thyroid cancer: analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid 6:305-310
4. Kebebew E, Clark OH (2000) Medullary thyroid cancer. Curr Treatm Opt Oncol 1:359-367
5. Vitale G, Caraglia M, Ciccarelli A et al (2001) Current approaches and perspectives in the therapy of medullary thyroid carcinoma. Cancer 91:1797-1808
6. Hoang-Vu C, Dralle H, Schroder S et al (1992) The nude rat is established as a model for endocrine studies: Regulation of thyroid function and xenotransplantation of a thyroid tumor cell line. Lab Anim Sci 42:164-167
7. Orlandi F, Caraci P, Mussa A et al (2001) Treatment of medullary thyroid carcinoma: An update. Endocr Relat Cancer 8:135-147
8. 90 yttrium-DOTA]-TOC treatment is associated with long-term survival benefit in metastasized medullary thyroid cancer: A phase II clinical trial. Clin Cancer Res 13:6696-6702
9. Cohen EG, Shaha AR, Rinaldo A et al (2004) Medullary thyroid carcinoma. Acta Otolaryngol 124:544-557
10. de Groot JW, Links TP, Sluiter WJ et al (2007) Locoregional control in patients with palpable medullary thyroid cancer: Results of standardized compartment-oriented surgery. Head Neck 29:857-863
11. Moley JF, DeBenedetti MK (1999) Patterns of nodal metastases in palpable medullary thyroid carcinoma: Recommendations for extent of node dissection. Ann Surg 229:880-887 discussion 887-888
12. Scollo C, Baudin E, Travagli JP et al (2003) Rationale for central and bilateral lymph node dissection in sporadic and hereditary medullary thyroid cancer. J Clin Endocrinol Metab 88:2070-2075
13. Modigliani E, Cohen R, Campos JM et al (1998) Prognostic factors for survival and for biochemical cure in medullary thyroid carcinoma: results in 899 patients. The GETC Study Group. Groupe d'etude des tumeurs a calcitonine. Clin Endocrinol 48:265-273
14. Machens A, Niccoli-Sire P, Hoegel J et al (2003) Early malignant progression of hereditary medullary thyroid cancer. N Engl J Med 349:1517-1525
15. Bollen EC, Goei R, van't Hof-Grootenboer BE et al (1994) Interobserver variability and accuracy of computed tomographic assessment of nodal status in lung cancer. Ann Thorac Surg 58:158-162
16. Gdeedo A, Van Schil P, Corthouts B et al (1997) Comparison of imaging TNM [(i)TNM] and pathological TNM [pTNM] in staging of bronchogenic carcinoma. Eur J Cardiothorac Surg 12:224-227
17. Adams S, Baum RP, Hertel A et al (1998) Comparison of metabolic and receptor imaging in recurrent medullary thyroid carcinoma with histopathological findings. Eur J Nucl Med 25:1277-1283
18. Baulieu JL, Guilloteau D, Delisle MJ et al (1987) Radioiodinated meta-iodobenzylguanidine uptake in medullary thyroid cancer. A French cooperative study. Cancer 60:2189-2194
19. Berna L, Cabezas R, Mora J et al (1995) 111 In-octreotide and 99m Tc(V)-dimercaptosuccinic acid studies in the imaging of recurrent medullary thyroid carcinoma. J Endocrinol 144:339-345
20. Berna L, Chico A, Matias-Guiu X et al (1998) Use of somatostatin analogue scintigraphy in the localization of recurrent medullary thyroid carcinoma. Eur J Nucl Med. 25:1482-1488
21. Guerra U, Pizzocaro C, Terzi A et al (1988) The use of 99m Tc(V)DMSA as imaging for the medullary thyroid carcinoma (MTC). J Nucl Med Allied Sci 32:242-247
22. Krausz Y, Rosler A, Guttmann H et al (1999) Somatostatin receptor scintigraphy for early detection of regional and distant metastases of medullary carcinoma of the thyroid. Clin Nucl Med 24:256-260
23. Mojiminiyi OA, Udelsman R, Soper ND et al (1991) Pentavalent Tc-99m DMSA scintigraphy. Prospective evaluation of its role in the management of patients with medullary carcinoma of the thyroid. Clin Nucl Med 16:259-262
24. Ugur O, Kostakglu L, Guler N et al (1996) Comparison of 99m Tc(V)-DMSA, 201 Tl and 99m Tc-MIBI imaging in the follow-up of patients with medullary carcinoma of the thyroid. Eur J Nucl Med 23:1367-1371
25. Brandt-Mainz K, Muller SP, Gorges R et al (2000) The value of fluorine-18 fluorodeoxyglucose PET in patients with medullary thyroid cancer. Eur J Nucl Med 27:490-496
26. 18 F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in patients with biochemical evidence of recurrent or residual medullary thyroid cancer. Ann Surg Oncol 11:786-794
27. Diehl M, Risse JH, Brandt-Mainz K et al (2001) Fluorine-18 fluorodeoxyglucose positron emission tomography in medullary thyroid cancer: Results of a multicentre study. Eur J Nucl Med 28:1671-1676
28. Gasparoni P, Rubello D, Ferlin G (1997) Potential role of fluorine-18-deoxyglucose (FDG) positron emission tomography (PET) in the staging of primitive and recurrent medullary thyroid carcinoma. J Endocrinol Investig 20:527-530
29. Musholt TJ, Musholt PB, Dehdashti F et al (1997) Evaluation of fluorodeoxyglucose-positron emission tomographic scanning and its association with glucose transporter expression in medullary thyroid carcinoma and pheochromocytoma: A clinical and molecular study. Surgery 122:1049-1060; discussion 1060-1041
30. 18F-FDG PET detection of lymph node metastases in medullary thyroid carcinoma. J Nucl Med 43:66-71
31. Simon GH, Nitzsche EU, Laubenberger JJ et al (1996) PET imaging of recurrent medullary thyroid cancer. Nuklearmedizin 35:102-104
32. Iagaru A, Masamed R, Singer PA et al (2007) Detection of occult medullary thyroid cancer recurrence with 2-deoxy-2-[F-18]fluoro-D- glucose-PET and PET/CT. Mol Imaging Biol 9:72-77
33. 18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma. Eur J Nucl Med Mol Imaging 34:1604-1609
34. 18F-DOPA positron emission tomography for tumour detection in patients with medullary thyroid carcinoma and elevated calcitonin levels. Eur J Nucl Med 28:64-71
35. 18 F]fluoro-L-dopa. J Nucl Med; 48(Supplement 2):138
36. Miyauchi A, Onishi T, Morimoto S et al (1984) Relation of doubling time of plasma calcitonin levels to prognosis and recurrence of medullary thyroid carcinoma. Ann Surg 199:461-466
37. 18 F-dihydroxyphenylalanine PET in patients with biochemical evidence of medullary thyroid cancer: Relation to tumor differentiation. J Nucl Med 49:524-531
38. 18 F-fluorodihydroxyphenylalanine PET in neuroendocrine tumors: Basic aspects and emerging clinical applications. J Nucl Med 49:573-586
39. 18F-FDG PET in restaging patients with medullary thyroid carcinoma and elevated calcitonin levels. J Nucl Med 48:501-507
40. Li S, Beheshti M (2005) The radionuclide molecular imaging and therapy of neuroendocrine tumors. Current Cancer Drug Targets 5:139-148
41. 18F]FDG-PET and improvement using a combined PET/CT scanner. Acta Med Austriaca 30:22-25
42. 18F-FDG PET, somatostatin receptor scintigraphy, and CT in metastatic medullary thyroid carcinoma: A clinical study and an analysis of the literature. Nucl Med Common 25:439-443
43. Wang Q, Takashima S, Fukuda H et al (1999) Detection of medullary thyroid carcinoma and regional lymph node metastases by magnetic resonance imaging. Arch Otolaryngol Head Neck Surg 125:842-848
44. Tung WS, Vesely TM, Moley JF (1995) Laparoscopic detection of hepatic metastases in patients with residual or recurrent medullary thyroid cancer. Surgery 118:1024-1029; discussion 1029-1030
45. Esik O, Szavcsur P, Szakall S Jr et al (2001) Angiography effectively supports the diagnosis of hepatic metastases in medullary thyroid carcinoma. Cancer 91:2084-2095
46. Adams S, Baum R, Rink T et al (1998) Limited value of fluorine-18 fluorodeoxyglucose positron emission tomography for the imaging of neuroendocrine tumours. Eur J Nucl Med 25:79-83
47. James C, Starks M, MacGillivray DC et al (1999) The use of imaging studies in the diagnosis and management of thyroid cancer and hyperparathyroidism. Surg Oncol Clin N Am 8:145-169
48. Raue F, Kotzerke J, Reinwein D et al (1993) Prognostic factors in medullary thyroid carcinoma: Evaluation of 741 patients from the German Medullary Thyroid Carcinoma Register. Clin Investig 71:7-12
49. Samaan NA, Schultz PN, Hickey RC (1989) Medullary thyroid carcinoma: prognosis of familial versus nonfamilial disease and the role of radiotherapy. Horm Metab Res 21:21-25